Physiologically based pharmacokinetic (PBPK) modeling offers a framework to integrate mechanistic data for physiology and biochemical processes and serves as a tool to predict internal exposure at target tissues for a wide range of exposure conditions in animals or humans ([@kfz211-B7]). In particular, PBPK models are an effective way to evaluate the potential impact of age-specific pharmacokinetics on internal exposure and to support risk assessment for potentially sensitive populations, such as younger ages ([@kfz211-B20]; [@kfz211-B63]). Modeling-based approaches address some of the challenges associated with using juvenile animal studies to infer the sensitivity in human children, such as species differences in maturation of physiology and biochemistry. *In vitro* to *in vivo* extrapolation (IVIVE) and *in silico*-based parameterization allows efficient development of PBPK models ([@kfz211-B22]; [@kfz211-B62]), especially for children where *in vivo* data generation is not possible ([@kfz211-B40]; [@kfz211-B63]).

Pyrethroids are among the most commonly used insecticides ([@kfz211-B38],[@kfz211-B39]). They act on the nervous system principally by interacting with voltage-gated sodium channels ([@kfz211-B49]). High dose studies have shown increased lethality in juvenile rats, raising the possibility of potential age sensitivity. Lethality was observed in 11- and 21-day old rats (LD50 of 5.1 and 11 mg/kg, respectively) at significantly lower doses than in adult rats (LD50 of 81 mg/kg) ([@kfz211-B48]). It is thus important to characterize the basis for this greater sensitivity in younger rats and assess its relevance to humans. Such observations could be the result of age-related pharmacokinetic differences as it is known that species differences exists in pyrethroids metabolism and its ontogeny ([@kfz211-B10]; [@kfz211-B14]; [@kfz211-B19]; [@kfz211-B43]). Our approach ([Figure 1](#kfz211-F1){ref-type="fig"}) combining life-stage PBPK modeling and IVIVE allows the incorporation of human relevant metabolism data and age-dependent physiological changes, thereby improving predictability of age-specific target tissue exposure. Species differences in the enzymes involved in pyrethroid metabolism ([@kfz211-B10]; [@kfz211-B14]) and the differential enzyme ontogeny reported between rats and humans suggest that metabolic competency in humans develops much earlier after birth compared with rats ([@kfz211-B19]; [@kfz211-B35]; [@kfz211-B43]; [@kfz211-B61]). This illustrates a critical limitation in using neonatal animal toxicity studies to infer human early-life sensitivity. Life-stage IVIVE-PBPK modeling thus provides an improved platform as it appropriately incorporates species and age-specific profiles when evaluating age-specific internal exposure to support risk assessment of pyrethroids in early ages.

![The approach building a generic physiologically based pharmacokinetic (PBPK) model for pyrethroids.](kfz211f1){#kfz211-F1}

Instead of developing a compound-specific PBPK model for each pyrethroid, we applied a single model structure to 8 pyrethroids (deltamethrin \[DLM\], *cis*-permethrin \[CPM\], bifenthrin, *trans*-permethrin \[TPM\], esfenvalerate, λ-cyhalothrin, β-cyfluthrin, and cyphenothrin) along with both compound-independent and compound-specific parameters. This single model structure is found in the graphical representation of our approach ([Figure 1](#kfz211-F1){ref-type="fig"}) as the generic life-stage PBPK model for pyrethroids. This approach was also previously demonstrated in the rat ([@kfz211-B50]).

MATERIALS AND METHODS
=====================

Structure of the Life-Stage PBPK Model
--------------------------------------

The structure of the human life-stage PBPK model for pyrethroids is shown in [Figure 2](#kfz211-F2){ref-type="fig"}. This multicompartmental model describes compound absorption and disposition in the body and incorporates a large data set of anatomical and physiological parameters with their age dependencies. The current model can simulate pyrethroid kinetics through oral ingestion and inhalation in single or multiple daily exposure scenarios and incorporates age-dependent human physiology, as well as maturation profiles of pyrethroid metabolism mediated by carboxylesterase (CES) and cytochrome P450 (CYP) enzymes in liver. Key assumptions of this human model structure and parameters are based on those evaluated in the rat model ([@kfz211-B50]). The model includes plasma and six tissue compartments: gastrointestinal tract, liver, fat, brain, slowly and rapidly perfused tissues. This multicompartmental model accounts for organ plasma flow rates and permeation into the organ tissue across a membrane between interstitial and cellular volume to achieve the right partitioning kinetics.

![Structure of the generic life-stage PBPK model for pyrethroids in humans. QLIVGI, QLIVH, QRP, QSP, QFAT, and QBRN refer to plasma flow to each tissue compartment. QLIV is the sum of QLIVGI and QLIVH. QAlv refers to the alveolar ventilation rate. Brain, fat, and slowly perfused tissue compartments are described as diffusion-limited tissues (the dotted lines represent the separation between tissue \[intracellular space\] and blood tissue \[extracellular space\]), whereas all other tissue compartments are described as flow limited.](kfz211f2){#kfz211-F2}

One salient feature of the model is inclusion of lymphatic absorption. Pyrethroids are highly lipophilic, therefore a certain fraction of the dose would be considered to be absorbed through the lymphatic pathway directly into the plasma compartment, by-passing the hepatic first pass metabolism ([@kfz211-B6]; [@kfz211-B23]; [@kfz211-B33]). The lymphatic absorption contribution via ingestion is assumed to be 100% in rats ([@kfz211-B50]). The rat assumption is based on oral gavage dosing, where the exposure occurs with a bolus lipid intake (corn oil) and generally at higher doses. This assumption is unrealistic for humans, where oral exposure occurs with a wide variety of lipid intake. In humans, the degree of lymphatic absorption would be more similar to lipid emulsion-based exposure rather than oil gavage with a substantial variability expected. The fraction of lymphatic absorption in humans was derived based on literature data ([@kfz211-B33]) with a mean around 10%. [@kfz211-B33] showed that the degree of intestinal lymphatic transport of highly lipophilic drugs and chemicals on coadministration of lipid-based formulations or in presence of food ranges from 1% to 45% suggesting a substantial degree of human variability in the degree of lymphatic absorption.

Based on the rat modeling "restrictive clearance" of a pyrethroid was included in the model structure. Initial evaluation of the IVIVE in rats showed that *in vivo* metabolic clearance of DLM, CPM, and TPM was lower than anticipated from *in vitro* estimated metabolic clearance. In other words, clearance of these pyrethroids appears to be restricted by one or more factors *in vivo* not accounted for in the initial model ([@kfz211-B50]). Three important parameters used to define the restrictive clearance of a pyrethroid are (1) an empirical adjustment factor (KMF) that reduces free concentration for metabolism in the liver, (2) the free faction of the compound in plasma that is available for tissue uptake (FuPLS), and (3) as explained above, a by-pass of hepatic first pass effect due to lymphatic absorption. In contrast to the KMF and lymphatic absorption values, which were estimated based on rat *in vivo* data and *in vitro* metabolism data, the FuPLS value is from human studies ([@kfz211-B46]). Full details of the study can be found elsewhere ([@kfz211-B46]), which sates that the fraction unbound in plasma (FuPLS) was significantly higher (2--2.5X) at birth to 1 week but reached and remained at adult levels in infants and children older than 4 weeks of age. Because the youngest age group included in the PBPK model is 6-month-old infants, the age-dependent effects of plasma protein binding are not relevant to our simulation. Therefore, we used a FuPLS of 0.1 in all the simulated ages in this study. Because KMF is an adjustment of enzyme affinity for the free concentration reflecting the difference between *in vitro* and *in vivo* conditions, a similar assumption of age-independence was appropriate. The fractional binding is not changing with age after 4 weeks and the unadjusted enzyme affinity is dependent on the shape and other characteristics of the active site, which is genetically controlled and does not vary with age. With respect to lymphatic absorption, the degree of intestinal lymphatic absorption can be influenced by digestibility of lipid-based vehicle as shown in rat studies because lipid content/type in the gut lumen affects the degree of stimulation of chylomicron production in enterocytes ([@kfz211-B6]; [@kfz211-B23]). Therefore, we can assume than the principal factor affecting lymphatic absorption is the lipid content of the food, not age. Once weaned, the lipid content of the food in the gut would not be different between children and adults.

The PBPK model describes only the plasma compartment, unlike the previously published [@kfz211-B55] that described the plasma and red blood cell (RBC) lumped into a whole-blood compartment. The RBC compartment was not included, as the data available in [@kfz211-B32] do not support substantial concentrations of DLM in RBCs, hence, elimination of the RBC compartment would not have much impact on the model predictions. Concentration of chemical in the plasma, RBCs, and whole blood can be defined using equation: $C_{blood} = C_{plasma} \times \left( {1 - {HCT}} \right) + C_{RBC} \times {HCT}$; where *C* describes concentrations (μM) and HCT (hematocrit). In cases where 100% of pyrethroids partition to the RBCs *C*~plasma~ = 0, *C*~blood~ = 0.45 × *C*~RBC~, and *C*~plasma~/*C*~blood~ = 0. Whereas, if 100% partition to the plasma is assumed, *C*~RBC~*=* 0 and *C*~blood~ = 0.55 × *C*~plasma~, and *C*~plasma~/*C*~blood~ = 1.82. Thus, if there is no partitioning of DLM to RBCs, the ratio of plasma to blood concentration should be approximately 1.8 in Mirfazaelian *et al.* study. However, the actual ratio from the data extrapolated from the paper is 2.1. The lack of exact concordance between these numbers can be attributed to variability in measurement and/or hematocrit. Hence, the available data do not support substantial concentrations in RBCs and are more consistent with DLM being almost exclusively confined to plasma. Based on this analysis of the *in vivo* results from [@kfz211-B32], we can conclude that the elimination of the RBC compartment has minimal impact on the model predictions. Furthermore, a nonpublished study has characterized the partitioning of DLM and CPM between erythrocytes and plasma *in vitro* and shows that DLM and CPM distributed evenly between RBC and plasma. The partition coefficient plasma:RBC was around 1.1 for DLM and between 0.5 and 1.1 for CPM. [@kfz211-B58] also shows a PBPK model of pyrethroid lumping RBC and plasma into blood.

Distribution in the flow-limited model is through plasma flow mainly, whereas the diffusion-limited model includes an additional term to describe diffusion through a capillary membrane. In our model, brain, fat, and slowly perfused compartments are described as diffusion limited to appropriately describe the time-delay in equilibration of pyrethroid concentrations between these tissues and plasma that is observed in the rat ([@kfz211-B26][@kfz211-B27]).

Elimination of pyrethroids occurs through metabolism in the liver. This is different from the rat where metabolic contribution of cytosolic CES to pyrethroid hydrolysis in plasma is also active. As CESs are not present in human plasma, no significant hydrolysis of pyrethroids in plasma is expected in humans ([@kfz211-B10]).

Model Parameters
----------------

### Physiological Parameters

Age-specific human physiological parameters, including body weight (BW), cardiac output, tissue weights (or volumes), and tissue plasma flows, were adapted from published life-stage models ([@kfz211-B9]; [@kfz211-B41]; [@kfz211-B51]; [@kfz211-B60]). These published life-stage models use the age-specific physiological parameters of women, which were adapted to represent men based on the most recent National Health and Nutrition Examination Survey (2005--2006) data. Growth curves for men and women used for modeling in this article are summarized in the [Supplementary 1](#sup1){ref-type="supplementary-material"}.

### Chemical-Specific Parameters

All other parameters are taken from the rat model ([@kfz211-B50]) and are listed in [Supplementary 2](#sup1){ref-type="supplementary-material"}, Table 1S. Assuming similarities in tissue composition between rat and human, the rat tissue partition coefficients were adapted for the human model. Tissue permeability-area cross products for diffusion were scaled to tissue volume^0.75^ instead of using a fixed value for all ages to reflect the diffusion surface area changes during growth. The values were adapted from the rat model.

### Enzyme Ontogeny

It is critical to obtain enzyme ontogeny data to apply *in vitro* metabolism data collected using expressed enzymes to predict age-specific metabolic clearance of pyrethroids *in vivo* ([@kfz211-B19]; [@kfz211-B63]). We collected the enzyme ontogeny information for the CYP and CES enzymes contributing to metabolism of 8 pyrethroids: (1) DLM, (2) CPM, (3) TPM, (4) esfenvalerate, (5) bifenthrin, (6) cyphenothrin, (7) cyhalothrin, and (8) cyfluthrin and conducted nonlinear regression analyses of those age-specific protein expression data from birth to young adulthood reported in the literature ([@kfz211-B17]; [@kfz211-B21]; [@kfz211-B30]; [@kfz211-B51]). Lognormal, hyperbolic, allosteric-sigmoidal, dose-response and, Gompertz growth curves were used, among which the best fit curve based on the Akaike Information Criterion and visual inspection was chosen to describe the maturation profiles of each enzyme expression as a fraction of the adult expression. Data are provided in [Supplementary 3](#sup1){ref-type="supplementary-material"}. In general, the data were best described as fractional expression of adult by hyperbolic, sigmoidal, or Gompertz models as follows: $$\left( 1 \right)~{Hyperbolic}~{eqn}:~\frac{{Adultmax}~ \times ~{Age}}{A50\%~ + ~{Age}},$$$$\left( 2 \right)~{Sigmoidal}~{eqn}:~\frac{{Adultmax}~ \times ~~{Age}^{h}}{{{Age}50\%}^{h}~ + ~{Age}^{h}},$$$$\left( 3 \right)~{Gompertz}~{eqn}:{Adultmax}~ \times ~e^{\ln({Adultmin}/{Adultmax})} \times ~e^{( - {Adult}50\%~ \times ~{Age})},$$where Adultmax is the maximum fractional expression of enzyme, Adultmin is the minimum fractional expression of enzyme (*Y*-intercept), A50% indicates age at which half-maximal fractional expression of enzyme is observed, Age is the actual age of the child, and *h* is the hill slope that reflects the steepness of the curve and presence of cooperativity. Gompertz model describes the ontogeny of most enzymes, including CYPs (1A2, 2C9, 2C19, 3A4) and CES, whereas the hyperbolic model (*n* = 1) was adequate for CYP2B6, and sigmoidal model fitted better for CYP2C8.

### In Vitro *to* In Vivo *Extrapolation*

The total intrinsic clearance of a given pyrethroid *in vivo* (CL~int_vivo_total~) was calculated as the sum of enzyme-specific *in vivo* intrinsic clearance (CL~int_vivo~) for all the enzymes that contribute to the metabolism of the pyrethroid. The enzyme-specific CL~int~ for each enzyme *in vivo* was extrapolated from the corresponding *in vitro* CL~int~ (CL~int\_vitro~) determined using the expressed human CYP and CES enzymes systems ([@kfz211-B16]).

#### Determination of in vitro intrinsic clearance (CL~int_vitro~)

The total intrinsic clearance of 8 pyrethroids (DLM, CPM, TPM, esfenvalerate, bifenthrin, cyphenothrin, cyhalothrin, and cyfluthrin) was assessed in human liver microsomes (HLMs) and cytosol ([Supplementary 3](#sup1){ref-type="supplementary-material"}). Interindividual variability in human liver metabolism being well known, we chose to use pooled microsomes and cytosol (150 adults: 75 males and 75 females) to better represent average human values for the selected pyrethroids used in this study. Some preliminary studies (data not shown) showed that the metabolism of DLM in rat (as CL~int~) determined in hepatocytes was comparable to the estimates based on the sum of the results from microsomes and cytosol. Furthermore, we used liver microsomes and cytosol because these subcellular fractions had all the phase I enzymes responsible for pyrethroid metabolism (ie, CYP and CES enzymes). In the phase I studies, *K*~M~ and *V*~max~ (Michaelis-Menten method) were determined to estimate the apparent CL~int~ for pyrethroids DLM, CPM, and TPM (substrate concentration range 0.1--5 µM) with primary aim to develop the PBPK model based on the DLM model as generic model (experiment design can be found in [@kfz211-B16]\]). For the phase II studies (5 additional pyrethroids including bifenthrin), a faster and simpler method of estimating the apparent CL~int~ was determined for human prediction (data not published yet). The similar physiochemical properties for all pyrethroids indicate similar solubility and based on the *K*~M~ of DLM, CPM, and TPM, a substrate concentration below *K*~M~ (0.1 µM) was selected for CL~int~ to ensure linear velocity and proper estimation of CL~int~. For the expressed enzymes, *K*~M~ and *V*~max~ were not determined, apparent CL~int~ were obtained from metabolism of 0.1 µM pyrethroid (experiment design can be found in [@kfz211-B15]\]). To determine individual enzyme's contribution toward this total intrinsic clearance, enzyme-specific CL~int_vitro~ for each CYP and CES enzymes were adjusted by enzyme abundance for a specific age. Among the CYP and CES enzymes screened, only the enzymes showing activity toward the 8 pyrethroids metabolism were used for IVIVE: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CES1, and CES2 ([@kfz211-B15]). Details on the experiment design and results in both systems can be found in [@kfz211-B16],b).

#### Scaling process

The CL~int_vitro~ from each expressed human enzyme was scaled to the corresponding *in vivo* CL~int~ in order to obtain the total CL~int_vivo~ for metabolism of a given pyrethroid in human liver. Inter-System Extrapolation Factors (ISEFs) were used for conducting IVIVE of the expressed enzyme CL~int_vitro~ values along with the (1) microsomal or cytosolic protein content, (2) liver weight, and (3) enzyme abundance in the target age populations ([@kfz211-B63]; [@kfz211-B62]). ISEF values used in this study are from [@kfz211-B57] and the age-dependent Microsomal protein per gram of liver (MPPGL) values are from [@kfz211-B4]. Cytosolic protein per gram liver (CPPGL) was used to perform IVIVE of cytosolic CES1 and 2, whereas MPPGL was used for CYPs and microsomal CESs. Contrary to MPPGL, there is little data available for age-dependent changes in CPPGL in the literature. For the adult, 80.7 mg CPPGL is reported ([@kfz211-B22]). Assuming that the ratio of MPPGL/CPPGL would be constant across ages, age-specific CPPGL values were calculated. Equations used for modeling MPPGL and CPPGL in this study are summarized in [Supplementary 3](#sup1){ref-type="supplementary-material"}. Information on the abundance of each CYP enzyme in adult liver for this calculation was taken from the published meta-analysis of several population studies ([@kfz211-B1]). For CES enzymes, published data were used ([@kfz211-B5]). In [@kfz211-B5], the abundance of each CES was given, except for cytosolic CES2 (CES2c). CES2c abundance was calculated based on the relative abundance of this enzyme, compared with the microsomal CES2 (CES2m) using the expression level ratio of CES2m/CES2c from [@kfz211-B21]. The total intrinsic clearance for all CES enzymes *in vivo* in adults was calculated as the sum of microsomal and cytosolic CES enzymes' CL~int_vivo~ values obtained using [equations 2](#E5){ref-type="disp-formula"} and [3](#E6){ref-type="disp-formula"}, respectively.

The relative contribution of the individual enzyme (CYPs and CESs) to the total *in vivo* CL~int_vivo~ (expressed as %) of a given pyrethroid is calculated as described below ([equation 4](#E7){ref-type="disp-formula"}). For each individual enzyme, the ontogeny was expressed as fractions of adult expression over time. To obtain an age-specific intrinsic clearance *in vivo* for each enzyme, the adult intrinsic clearance for the corresponding enzyme (CL~int_enzyme_vivo_adult~) was scaled based on the enzyme ontogeny. The estimated CL~int_vivo~ values for each enzyme at a given age were then summed to calculate the total liver intrinsic metabolic clearance (CL~int_vivo_total~) of a given pyrethroid for that age *in vivo*. All the final *in vivo* clearance values for all the ages are provided in [Supplementary 3](#sup1){ref-type="supplementary-material"}: final clearance values. $${\left. \text{CL}_{\text{int}\_\text{CYP}\_\text{vivo}\_\text{adult}} = {~\text{CL}}_{\text{int}\_\text{CYP}\_\text{vitro}} \times \text{ISEF}\_\text{CYP} \times \text{MPPGL} \times \text{LW} \times \text{CYP} \right.\_\text{abundance}},$$$${\left. \text{CL}_{\text{int}\_\text{CESm}\_\text{vivo}\_\text{adult}} = {~\text{CL}}_{\text{int}\_\text{CESm}\_\text{vitro}} \times \text{ISEF}\_\text{CES} \times \text{MPPGL} \times \text{LW} \times \text{CESm} \right.\_\text{abundance}},$$$${\left. \text{CL}_{\text{int}\_\text{CESc}\_\text{vivo}\_\text{adult}} = {~\text{CL}}_{\text{int}\_\text{CESc}\_\text{vitro}} \times \text{ISEF}\_\text{CES} \times \text{CPPGL} \times \text{LW} \times \text{CESc} \right.\_\text{abundance}},$$$${\%~\text{Contribution} = \frac{\text{CL}_{\text{int}\_\text{enzyme}\_\text{vivo}\_\text{adult}}}{{\text{Total}~\text{hepatic}~\text{CL}}_{\text{int}\_\text{vivo}\_\text{adult}}} \times 1{00}}.$$

In the PBPK model, the total CL~int_vivo~ of a pyrethroid estimated from *in vitro* data ([equation 5](#E8){ref-type="disp-formula"}) is referred to as CL~int_vivo_estimated~. As noted previously, an empirical free concentration adjustment factor (KMF) was applied to adjust this *in vivo* hepatic CL~int~ (CL~int_vivo_estimated~) to obtain the actual CL~int_vivo~: $${\text{CL}_{\text{int}\_\text{vivo}} = \frac{\text{CL}_{\text{int}\_\text{vivo}\_\text{estimated}}}{\text{KMF}}}.$$

A single value of KMF was used for all 8 pyrethroids and for all the ages simulated in this study as this factor was shown to be applicable in describing the observed restricted clearance *in vivo* regardless of pyrethroid identity or age of the animals in the rat study ([@kfz211-B50]).

### Sensitivity Analysis and Uncertainty

To evaluate the relative impact of each of the model parameters on the selected measure of internal exposure, in this study the maximum concentration (*C*~max~) in the brain, a sensitivity analysis (SA) was performed. In our preliminary simulations, SA was not affected by a low or high dose (data not shown), hence in the current study, the SA was conducted for two ages (1 and 25 years old) and at one dose (1 mg/kg BW). The SA was also conducted at steady state (last *C*~max~ at steady state corresponding to 119--120 days). The sensitivity coefficient (SC) for each parameter analyzed was calculated as below ([@kfz211-B64]): $$\text{SC} = \text{fractional}~\text{change}~\text{in}~\text{model}~\text{output}/\text{fractional}~\text{change}~\text{in}~\text{parameter}.$$

After oral exposure, each parameter was individually increased by 1% of their original value, whereas the other parameters were held constant to determine the SC values. All the parameters from [Supplementary Table 1S](#sup1){ref-type="supplementary-material"} in [Supplementary 2](#sup1){ref-type="supplementary-material"} were changed during the SA with the exception of the body surface area, the fraction of blood in tissue, and the air blood partition coefficient. A SC of 1 represents 1:1 relationship between the change in the parameter and the internal dose metric of choice. A negative SC indicates the given parameter influences the dose metric in an inverse (opposite) direction. The SCs are grouped in 3 categories, high (absolute values ≥ 0.5), medium (absolute values ≥ 0.2 but \< 0.5), or low (absolute values ≥ 0.1 but \< 0.2), according to the International Program on Chemical Safety guideline ([@kfz211-B67]).

### Model Simulations

The model was developed in acslX (version 3.1.4.2; The Aegis Technologies Group, Inc, Huntsville, Alabama) and was translated to R (model equations available in [Supplementary 4](#sup1){ref-type="supplementary-material"}). The R model was run using the model interface, PLETHEM (Pendse *et al.*, submitted), for all model simulations.

Some simulations of the kinetic profile of the 8 pyrethroids in brain after a single oral dose every day during 14 days in adult (25Y) and children (1Y) can be found in [Supplementary 2](#sup1){ref-type="supplementary-material"}, [Figure S5](#sup1){ref-type="supplementary-material"}. Steady state is reached at 120 days but in the purpose of showing the kinetic profile, we stopped the simulation at 14 days.

The model for the 8 pyrethroids was run with a daily oral dose of 1 mg/kg with Monte-Carlo (MC) analysis in males of four different ages (1-, 5-, 19-, and 25-year old) to compare the internal exposure in the target tissue brain (*C*~max~) across ages. Environmental Protection Agency has identified young children as a population of concern because dietary assessment identified this age group as the most highly exposed as children are still engaged in hand-to-mouth activities and have significant contact with treated surfaces (eg, carpet, turf, and pets).

Monte-Carlo simulations were performed with 1000 iterations to perform population-level simulations, at which the convergence was achieved. Further increase in the number of iterations to 5000 and 10 000 did not make a substantial difference in the convergence achievement. Monte-Carlo analysis was performed to incorporate interindividual variation in the values of parameters across the population to predict the distribution of internal doses. Based on the SA, parameters with SC over 0.2 were varied for MC analysis and were randomly sampled from their distributions, whereas other parameters were fixed. Model parameters that varied for the MC analysis and their distributions are listed in [Table 1](#kfz211-T1){ref-type="table"}.

###### 

Parameters Changed for the Monte-Carlo Analysis

  Parameters                                         Distribution[^a^](#tblfn1){ref-type="table-fn"}  CV     Reference
  ------------------------------------------------- ------------------------------------------------- ------ -----------------------------------
  Body weight (BW)                                                          L                         0.22   [@kfz211-B37]
  Hematocrit (HTC)                                                          L                         0.06   [@kfz211-B37]
  Cardiac output (CARDOUTPC)                                                L                         0.2    [@kfz211-B54]
  Fraction unbound in plasma (FuPLS)                                        L                         0.1    [@kfz211-B46]
  Brain fractional plasma flow (FRBRNC)                                     N                         0.1    [@kfz211-B37]
  Brain partition coefficient (PBRN)                                        L                         0.3    [@kfz211-B8]
  Brain permeability (PABC)                                                 L                         0.3    Assumption
  Liver volume (VOLLIVERC)                                                  N                         0.16   [@kfz211-B37]
  Liver fractional plasma flow (FRLIVC)                                     N                         0.16   [@kfz211-B37]
  Metabolic constant (VKM1C)                                                L                         0.5    [@kfz211-B54]
  Empirical adjustment factor (KMF)                                         L                         0.5    Assumption
  Fat volume (VOLFATC)                                                      N                         0.41   [@kfz211-B37]
  Fraction absorbed to systemic circulation (SWH)                           L                         1.44   Calculated based on [@kfz211-B33]

Sample distributions obtained from [@kfz211-B36] (N, normal; L, lognormal) ([@kfz211-B36]).

[@kfz211-B37] showed that for the physiological parameters used in our MC analysis, the coefficient of variation (CV) between children and adult do not vary substantially ([@kfz211-B37]). To avoid the selection of extreme outliers, distributions were symmetrically truncated. For the parameters with a normal distribution in MC, we applied a truncation above and below two standard deviations (SD) from the mean. Parameters with a lognormal distribution are defined using the mean and SD of the log-transformed distribution. The truncation was applied to the transformed distribution in the same way as to the normal distribution.

RESULTS
=======

### Development of Enzyme Ontogeny

*In vitro* expressed enzyme studies indicated that CYP1A2, CYP3A4, CYP2C9, CYP2C19, CYP2B6, CYP2C8, CYP3A5, CES1-m, CES1-c, CES2-m, and CES2-c exhibit metabolic activity toward the 8 pyrethroids (data not shown). Maturation profiles vary for different enzymes ([Figure 3](#kfz211-F3){ref-type="fig"} and [Supplementary 3](#sup1){ref-type="supplementary-material"}); for example, CES enzymes are expressed at adult levels at 6 months of age, whereas CYP1A2 and 2C19 are expressed at or near adult levels by 5--10 years old. For all the other enzymes analyzed in this study, their expression increases during the first 6 months of life to a level that is close to that of the adult (approximately 80%) and reach the adult level just thereafter.

![Nonlinear regression fits for major hepatic xenobiotic metabolizing enzymes involved in pyrethroid metabolism. Here, "m" represents the carboxylesterase (CES) enzyme in microsomes and "c" represents that in cytosol.](kfz211f3){#kfz211-F3}

### Metabolism Profiles

Metabolism profiles and rates are similar for DLM, TPM, and cyphenothrin, likewise, CPM has comparable profiles to esfenvalerate, cyhalothrin, and cyfluthrin, whereas bifenthrin is quite distinct from others in its metabolism profile ([Figure 4](#kfz211-F4){ref-type="fig"} and [Supplementary 2, Figure 1S](#sup1){ref-type="supplementary-material"}). Therefore, 3 pyrethroids were selected as representatives of all 8 pyrethroids in this article, the 5 remaining pyrethroids results are included in the [Supplementary Files](#sup1){ref-type="supplementary-material"}. These 3 pyrethroids are DLM (metabolized mainly by CES enzymes), CPM (metabolized by CYP and CES enzymes), and bifenthrin (metabolized only by CYP enzymes). The relative contribution of individual enzyme to the overall CL~int~ of DLM, CPM, and bifenthrin at different ages is shown in [Figure 4](#kfz211-F4){ref-type="fig"}. For DLM, enzyme contribution followed the order: CES1-m \> CES1-c \> CYP3A4 \> CYP2C19 \> CYP2B6 \> CYP1A2 \> CES2-m ≈ CES2-c. For CPM, enzyme contribution followed the order: CES1-m \> CES1-c \> CES2-c \> CES2-m \> CYP2C19 \> CYP2B6 \> CYP2C9 \> CYP3A4. For bifenthrin, enzyme contribution followed the order: CYP2C19 \> CYP2C9 \> CYP3A4 \> CYP2C8 \> CYP3A5. CYP3A5 and 2D6 have not been incorporated into the analysis, due to their negligible contribution of \< 0.5%. [Figure 4](#kfz211-F4){ref-type="fig"} clearly shows how different the enzyme contribution profiles are for these 3 representative pyrethroids, indicating that CESs are the major players in the metabolism of DLM and CPM with more than 70% contribution, whereas CYPs are mostly implicated in the metabolism of other pyrethroids, in particular, bifenthrin. The relative contribution of each enzyme for all other pyrethroids to total metabolism at different ages is provided in [Supplementary 2, Figure 1S](#sup1){ref-type="supplementary-material"}, and [Supplementary 3](#sup1){ref-type="supplementary-material"}.

![Relative contribution of cytochrome P450 (CYP) and CES enzymes to the metabolism of deltamethrin (DLM), *cis*-permethrin (CPM), and bifenthrin. Microsomal CES1 is denoted by CES1-m, cytosolic CES1 by CES1-c, microsomal CES2 by CES2-m, and cytosolic CES2 by CES2-c.](kfz211f4){#kfz211-F4}

### *Estimation of the Age-Specific Intrinsic Clearance for a Pyrethroid* In Vivo

The *in vivo* CL~int~ values that were calculated from IVIVE for DLM, CPM, and bifenthrin using the expressed enzyme data and the total CL~int_vivo~ from cytosol and microsomes are shown in [Figure 5](#kfz211-F5){ref-type="fig"}. CL~int_vivo~ values for the 5 other pyrethroids are provided in [Supplementary 2](#sup1){ref-type="supplementary-material"}, [Figure S2](#sup1){ref-type="supplementary-material"}. The expressed enzyme results were used to calculate relative contribution of each enzyme to the total CL~int_vivo~ of a given pyrethroid, whereas the pooled microsomal and cytosolic CL~int_vivo~ data for the pyrethroid were used to estimate the total CL~int_vivo~. When adjusted to age-specific BW, for all 3 representative pyrethroids (DLM, CPM, and bifenthrin), there is no differences in the CL~int~*in vivo* between ages.

![Intrinsic hepatic clearance of DLM, CPM, and bifenthrin in males of different ages.](kfz211f5){#kfz211-F5}

#### Sensitivity analysis

Most of our model parameters are reported to have medium or low uncertainty. [Figure 6](#kfz211-F6){ref-type="fig"} presents SA results for brain concentration (*C*~max~) for DLM, CPM, and bifenthrin that hold similar ranking among all 8 pyrethroids. Sensitivity analysis results for the 5 other pyrethroids are provided in [Supplementary 2](#sup1){ref-type="supplementary-material"}, [Figure S3](#sup1){ref-type="supplementary-material"}. Overall, our SA shows that brain partition coefficient and unbound fraction in plasma are the most sensitive parameters for all 8 pyrethroids.

![Sensitivity analysis indices after oral absorption for DLM (A), CPM (B), and bifenthrin (C). *C*~max~ in brain was evaluated during the sensitivity analysis.](kfz211f6){#kfz211-F6}

Other physiological parameters that were highly sensitive for most of the 8 pyrethroids, includes BW, cardiac output, hematocrit, plasma flow to the liver, and fat volume. For early ages, the plasma flow to the brain, the liver, and fat volume and the rapidly perfused tissues were sensitive parameters. Hematocrit (HCT) was more sensitive for DLM compared with CPM. Hematocrit refers to the percentage of total blood volume composed of RBCs and thus determines the plasma volume in our model as described in *V*~plasma~ = *V*~blood~ × (1 − HCT). Pyrethroids are bound to plasma proteins and only the unbound fractions are subjected to clearance. With higher value of HCT, the plasma volume will be lower which will reflect as less protein binding and higher free fraction (FuPLS) available for clearance. Clearance of DLM is higher than CPM with similar protein binding. Thus, the amount of compound in the plasma available for clearance will be more important for DLM than CPM. Hence in sensitive analysis, when HCT is varied its influence is weightier for DLM than CPM.

Liver metabolic clearance was a highly sensitive parameter for CPM and bifenthrin, however, it showed low to moderate sensitivity for DLM at early ages and adult, respectively. DLM, CPM, and bifenthrin are all rapidly cleared by metabolism in early and adult ages, but DLM metabolism is faster than that of CPM and bifenthrin (due to DLM being metabolized mainly by CES) making a difference in the sensitivity of metabolic clearance to brain *C*~max~ among the 3 compounds. For CPM and bifenthrin, the most sensitive parameters also included the brain partition coefficient, followed, in order, by KMF \> the liver metabolic clearance \> the liver volume \> the unbound fraction in plasma \> the lymphatic absorption. Brain permeability is less sensitive for all the pyrethroids.

The LYMPSWTCH parameter is more sensitive for DLM compared with CPM. The LYMPSWTCH parameter corrects for the differing contribution of lymphatic absorption after oral exposure as fraction of total absorption. It is known that absorption of a highly lipophilic compound or drug with log *P* \> 5 occurs through lymphatic vessels to a varying extent depending on the fat content in diet in addition to the usual absorption path through portal veins ([@kfz211-B6]; [@kfz211-B23]). Deltamethrin is known to have a log *K*~ow~ of 4.61, whereas the log *K*~ow~ for CPM is 6.1. The difference in the chemical structure may explain the difference in sensitivity for the lymphatic absorption.

The uncertainty of a model reflects the level of confidence in model predictions. A sensitivity/uncertainty matrix can be used to determine the overall importance of a parameter---our analysis was intended to be qualitative mainly to identify the areas for future studies/data collection. Two matrices for DLM and CPM are shown in [Supplementary Table 2S](#sup1){ref-type="supplementary-material"} in [Supplementary 2](#sup1){ref-type="supplementary-material"}. The parameters included in these 2 matrices are the ones that showed sensitivity in the SA. The lymphatic absorption as well as KMF and the brain permeability show some uncertainty. Indeed, the lymphatic absorption parameter was calculated based on the literature and the KMF parameter was introduced to the model to reduce the clearance to better fit the *in vivo* data. Permeability parameters were estimated which increase the uncertainty of the model, especially in brain, the target organ. This matrix was done for DLM and CPM only because they were the 2 pyrethroids originally used to develop the life-stage PBPK model. However, the uncertainty would remain the same for the 6 additional pyrethroids.

#### Simulation of pyrethroid internal exposure in different ages

The *in vivo* hepatic intrinsic clearances (CL~int_vivo~) for DLM, CPM, and bifenthrin are listed in [Table 2](#kfz211-T2){ref-type="table"}. Hepatic metabolic clearance of a pyrethroid in our model is determined by 4 factors: hepatic CL~int_vivo~, hepatic blood flow (QLIV), unbound fraction in plasma (FuPLS), and the free concentration adjustment factor, KMF. For DLM, CPM, and bifenthrin, the CL~int_vivo~ vary slightly with age. Only bifenthrin has a CL~int_vivo~ lower than the liver plasma flow at younger ages.

###### 

Model Estimated Hepatic Intrinsic Clearance (CL~int_vivo~) for DLM, CPM, and Bifenthrin in the Male

  Age (year)   QLIV (l/h)   DLM Hepatic CL~int_vivo~ (l/h)   CPM Hepatic CL~int_vivo~ (l/h)   Bifenthrin Hepatic CL~int\ vivo~ (l/h)
  ------------ ------------ -------------------------------- -------------------------------- ----------------------------------------
  0.5          12.2         224                              20                               5
  2            18.3         375                              34                               10
  5            24.0         565                              51                               16
  12           38.3         1282                             115                              36
  19           49.9         2066                             186                              58
  25           50.7         2417                             217                              67

The mean *C*~max~ in brain following a daily single oral dose (1 mg/kg) of each pyrethroid for 120 days in males of 4 different ages was obtained by MC simulations. Our model simulation showed that the difference in internal exposure (*C*~max~) at the target tissue (brain) in child (1Y, 5Y, 19Y) is similar to that in adults (25Y) for all 3 representative pyrethroids, DLM, CPM, and bifenthrin ([Figure 7](#kfz211-F7){ref-type="fig"}). The results for the 5 other pyrethroids are provided in [Supplementary 2](#sup1){ref-type="supplementary-material"}, [Figure S4](#sup1){ref-type="supplementary-material"}.

![Brain *C*~max~ after a daily single DLM (A), CPM (B), and bifenthrin (C) oral dose at 1 mg/kg, respectively in males 4 different ages. One thousand individuals for each group were simulated. Horizontal line bisecting large rectangle, median; large rectangle, lower and upper quartiles; whiskers, 5th and 95th percentiles.](kfz211f7){#kfz211-F7}

DISCUSSION
==========

This research describes the development and application of an IVIVE supported life-stage human PBPK model for the evaluation of age-related sensitivity to pyrethroids exposure.

Studies indicate age-related differences in internal exposure to pyrethroids in the brain ([@kfz211-B47]; [@kfz211-B48]). Our rat model ([@kfz211-B50]) demonstrates that the observed age-related differences are largely determined by the differences in metabolic capacity for pyrethroids between the young and the adult and secondarily by age-related changes in physiology. To evaluate the human relevance of this, understanding and consideration of the ontogeny of pyrethroid metabolizing enzymes is critical. Several investigations have reported enzyme ontogeny for human hepatic xenobiotic metabolizing enzymes ([@kfz211-B5]; [@kfz211-B21]; [@kfz211-B34]; [@kfz211-B42]; [@kfz211-B61]; [@kfz211-B65]). However, uncertainties still exist for many of these ontogeny data as the pediatric sample size and quality varied widely in these investigations. Another confounding factor is targeted age groups; for some studies, small sample size for early ages underrepresented their ontogeny trajectory, whereas for other studies, limited number of samples was distributed over the full pediatric age range. We therefore generated ontogeny profile for enzymes involved in pyrethroid metabolism as a continuous function using the protein expression data from collaborative efforts with Dr. Ron Hines (data not published) allowing development of equations to predict enzyme expression at any desired age from birth to adulthood.

The expressed enzyme-based IVIVE approach was employed to tackle the challenge of obtaining pediatric liver tissue samples, as well as uncertainties in the *in vitro* metabolic constants obtained from them. In fact, scaling *in vitro* measured metabolic constant to *in vivo* metabolism parameters has become common practice in pharmaceutical PBPK models for pediatrics ([@kfz211-B3]; [@kfz211-B24]; [@kfz211-B29]). Using the expressed enzyme-based IVIVE, *in vivo* metabolic clearance was higher than that from subcellular fraction-based IVIVE for most of the tested pyrethroids. For example, total *in vivo* CL~int~ values estimated with expressed enzymes for DLM and CPM were 36,782 and 70,481/h/kg liver, respectively, but with HLMs and cytosol (subcellular fraction), the total CL~int_vivo~ were estimated to be 7,418 and 6,68 l/h/kg liver, respectively (data not shown). Whereas for bifenthrin, the CL~int_vivo~ values were similar in the two systems (145 and 2,06 l/h/kg liver for expressed enzymes and subcellular fraction, respectively). Variability in enzyme abundance in humans potentially explains the differences in the estimated *in vivo* clearance values between the two systems. For the current IVIVE approach, protein levels of CES1 and CES2 reported in [@kfz211-B5] were used (most recent report based on a large cohort of well-characterized pediatric and adult subjects), which were higher than those reported in some other studies ([@kfz211-B14]; [@kfz211-B16]; [@kfz211-B30]; [@kfz211-B44]). Such differences in enzyme abundance in different reports might be due to the origin of microsomal samples or the accuracy of difference in the quantification methods used. However, the differences in the estimates between the two systems are much less than the expected human variability inferred from the variation in metabolic enzyme abundances ([@kfz211-B1]; [@kfz211-B5]; [@kfz211-B25]). Therefore, the expressed enzyme results were used to calculate relative contribution of each enzyme to the total CL~int_vivo~ of a given pyrethroid, whereas the pooled microsomal and cytosolic CL~int_vivo~ data for the pyrethroid were used to estimate the total CL~int_vivo~. These experiments were done in subcellular fraction and it is interesting to also look at the values in other systems like hepatocytes. In [@kfz211-B59], they measured an *in vivo* CL~int~ for CPM in cryopreserved hepatocytes of 60 l/h/kg liver. Use of freshly isolated or cryopreserved primary hepatocytes in suspension for *in vitro* predictions for rapidly cleared chemicals is a more adequate system compared with other matrices. Although use of monolayer or sandwich-culture of hepatocytes extends viability but there is clear phenotypic instability and rapid decline of metabolic competence within a few hours ([@kfz211-B11]; [@kfz211-B12]). Further more, in Willemin study, the CYP activities of their hepatocyte lots were in the low range of activities reported by others. Hence, the differences in rate of metabolism are mostly due to differences in CYP content in the two different systems. Our *in vitro* metabolism data and IVIVE analysis showed that CES enzymes are the major contributor to metabolism in humans for most of the pyrethroids except for bifenthrin, for which CYPs were largely responsible for metabolism. For all of the 8 pyrethroids, the metabolism is very rapid, therefore the hepatic metabolism is only limited by liver blood flow regardless of age in humans. This holds true for bifenthrin as well but only for adults. In younger ages, metabolism is a limiting factor. The sum of CES1 levels in both liver microsomes and cytosol, is around 30 times that of microsomal CYP3A4 ([@kfz211-B1]) resulting in a very efficient hydrolysis of the compound metabolized by this class of enzyme. In addition, total *in vivo* hepatic clearance of each pyrethroid in early ages would be higher than that in adults, even if there is no difference in hepatic CL~int_vivo~ ([Figure 5](#kfz211-F5){ref-type="fig"}), as the relative liver blood flow and liver weight are both higher per BW in early ages. Note that relative values are referred to here as the absolute liver weight or liver plasma flow increase with age, but their fraction of the total BW or total cardiac output, respectively, decreases. These age-dependent changes in physiological factors together with the rapid metabolic clearance contribute to an internal exposure in the target tissue in children lower than or comparable to that in adults in humans in response to the same level of exposure to a given pyrethroid.

Restrictive clearance was used to account for the difference between *in vitro*-derived and *in vivo*-derived intrinsic clearance observed, as was done in the rat ([@kfz211-B50]). Other pyrethroid PBPK models ([@kfz211-B66]; [@kfz211-B32]; [@kfz211-B56]) fit the plasma time course data reasonably well without adjusting *in vitro* clearance rates and do not separate the free and bound fractions of pyrethroids ([@kfz211-B55]). It is now known that nonspecific, noncovalent binding of pyrethroids to microsomes was likely in the *in vitro* incubation conditions used to parameterize these models. As a result, the nonspecific binding *in vitro* would mask the restricted clearance of pyrethroids *in vivo*. Importantly, it should be noted that the current description of restricted clearance in the PBPK model does not imply that clearance of pyrethroids is slow. Although clearance is reduced, pyrethroids are rapidly and completely cleared from the body at doses relevant to actual human exposure as indicated by results from human volunteer studies using several pyrethroids ([@kfz211-B38],[@kfz211-B39]).

Another factor in the predicted clearance is the fraction of lymphatic absorption. Higher lymphatic absorption was used in the rat than in the human model. Lymphatic absorption is well known for highly lipophilic drugs and chemicals, the degree of which varies in humans ranging from 1% to 45% depending on coadministration of lipid-based formulations or in the presence of food ([@kfz211-B33]). Considering the expected substantial degree of human variability in intestinal lipid content, the degree of lymphatic absorption is likely highly variable.

Some juvenile animal studies have raised concerns for potentially higher sensitivities to the effect of pyrethroid exposure in infants and children ([@kfz211-B48]). Our rat model data corroborates this pharmacokinetic determination of the sensitivity between young and adult rats ([@kfz211-B50]). In contrast, the human model represented in this manuscript did not predict any substantial difference in brain *C*~max~ in different age groups for any of the three case pyrethroids ([Figure 7](#kfz211-F7){ref-type="fig"}). Hepatic CYPs and CES are important metabolizing enzymes for detoxification and elimination of pyrethroids in both rats and humans ([@kfz211-B2]; [@kfz211-B10]; [@kfz211-B14], [@kfz211-B13]; [@kfz211-B45]), but significant species differences exist in the relative contribution of various CYPs and CES enzymes ([@kfz211-B13]; [@kfz211-B45]) as was confirmed by our *in vitro* expressed enzyme results. This species difference is likely one of the factors for the age-related sensitivity observed in rats but not in humans as the major enzyme for pyrethroid metabolism in human is CES, which shows a rapid maturation after birth. In fact, differences in the developmental changes in the expression of CYP and CES enzymes are evident between rats versus humans ([@kfz211-B2]; [@kfz211-B17][@kfz211-B18]; [@kfz211-B21]; [@kfz211-B27]; [@kfz211-B28]; [@kfz211-B52]; [@kfz211-B53]). The earlier maturation of metabolic competency of hepatic CYP and CES enzymes in humans likely allows juvenile humans to detoxify pyrethroids to a much greater extent compared with rats ([@kfz211-B10]; [@kfz211-B18]; [@kfz211-B21]; [@kfz211-B52]). Collectively, the ontogeny of the pyrethroid metabolizing enzymes is a key driver for the age-related sensitivity observed in rats saturating the enzyme capacity in juvenile animals after the high dose used in the toxicity study ([@kfz211-B48]).

The ultimate goal of the life-stage IVIVE-PBPK modeling framework presented here is to support risk assessments for potentially sensitive populations of early ages for pyrethroids as a chemical class. From this perspective, the most important contribution of our case studies is a demonstration of the development of a generic model structure for pyrethroids using a common set of parameters apart from compound-specific metabolism. The clearance-based read-across strategy to address age-related sensitivity using life-stage PBPK models and IVIVE can be readily applied to other groups of chemicals and support internal exposure-based risk assessment for potentially sensitive populations.
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